Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2021 | CNM-Au8 gold nanocatalysts to slow disease progression in ALS

Robert Glanzman, MD, FAAN, Clene Nanomedicine Inc, Salt Lake City, UT, outlines the details of the ongoing Phase II double-blind placebo-controlled RESCUE-ALS trial (NCT04098406) of CNM-Au8 in early amyotrophic lateral sclerosis (ALS). Riluzole and edaravone represent the only FDA-approved therapies for ALS, and neither have resulted in substantial disease-modifying effects. CNM-Au8, an aqueous suspension of pure gold nanocrystals, is being assessed for safety and efficacy over a 36-week period, using motor unit number index (MUNIX) as a measure of motor neuron loss. This interview took place during the ACTRIMS Forum 2021.


Dr Glanzman is an employee of Clene Nanomedicine.